sleepImageAcross the globe more than a million exhausted people with sleep apnea—a sleep and breathing disorder caused when throat muscles relax and block the airway during sleep—get into car accidents, causing over a thousand deaths every year.

 Apnea is linked to obesity, heart disease, diabetes, an additional $3.4 billion in medical costs, and $16 billion in auto collision costs. Even though apnea has telltale signs (loud snoring, daytime fatigue), it remains totally undiagnosed in almost 75 percent of the people.

Polysomnography, the only diagnostic sleep study for sleep apnea is not cheap generally. the standard medical sleep study, requires a medical technician to attach 22 wires to a person’s body and monitor them all night long. The average cost is nearly $3,000. This is quite an out of the pocket expense for anyone. Follow-up tests are even more cost bearing and burdensome. The idea of doing clinical sleep studies once a month to monitor progress is a diagnostic crack-pipe fantasy. Read the rest of this entry

sleep disorder in military personnelA recently concluded research study attempted describing the prevalence of sleep disorders in military personnel referred for polysomnography and identify relationships between demographic characteristics, comorbid diagnoses, and specific sleep disorders.

This retrospective cross-sectional study was conducted with the military medical treatment facility involving active duty military personnel with diagnostic polysomnogram in 2010.

Primary sleep disorder rendered by review of polysomnogram and medical record by a board certified sleep medicine physician. Demographic characteristics and conditions of posttraumatic stress disorder (PTSD), mild traumatic brain injury (mTBI), anxiety, depression, and pain syndromes determined by medical record review. Read the rest of this entry

According to research presented at the 20th Anniversary Meeting of  the American Academy of Dental Sleep Medicine (AADSM), the  apnea-hypopnea index (AHI) in patients with severe obstructive sleep  apnea (OSA) was more improved by a combination treatment of a mandibular  advancement splint (MAS) and positive airway pressure (PAP) therapy  than by continuous positive airway pressure (CPAP) therapy alone.

Results show that without lowering the pressure substantially, CPAP  tolerance can be improved and severe OSA can be effectively treated  using a MAS that physically supports and stabilizes the position of  nasal pillows (TAP-PAP). Read the rest of this entry

How A Sleep Center Diagnose Sleep Apnea

Fragmented sleep, loud snoring, debilitating daytime fatigue, low oxygen levels, missed work days, morning headaches and problems remembering and concentrating are among the symptoms of sleep apnea disorder, the most common sleep disorder.

According to estimates there are more than 18 million Americans suffer from the deadly disorder called sleep apnea.

One of the first steps is generally to undergo an overnight sleep evaluation, or “nocturnal polysomnogram.” It is commonly known as overnight sleep study at the sleep center.

Patients spend one night in a special laboratory or a bedroom hooked up to sophisticated computer equipment that monitors heart, lung and brain activity; breathing patterns; arm and leg movements; and blood oxygen levels. The room generally includes soft lighting; a comfortable bed; a quiet, calming atmosphere; television; and other amenities to help the patient sleep.

In some cases, a portable home monitoring device can also be used to track heart rate, blood oxygen level, airflow and breathing patterns. Unfortunately, however, it does not always provide the most effective readings. An overnight, in-center polysomnogram may still be needed.

Most common sleep problems can be successfully treated, and there are a variety of treatment options.“I think most people agree that sleep is important to overall health, but they fail to tell their doctors when they’re having problems — this is probably due to a variety of reasons, but a common one includes uncertainty about the treatments,” says Dennis Auckley, M.D., director of the MetroHealth Center for Sleep Medicine.

Dr. Auckley leads a team of six Valerie Ross, CNP, and Jan Steinel RRT, CNP, are also specially trained members of the team that provides clinical diagnosis and treatment of the full spectrum of sleep disorders in adults and children at three specially equipped Sleep Center facilities: at MetroHealth’s main campus just south of downtown Cleveland, in Independence, and — new this year — in Westlake. Patients are also seen at The Senior Health & Wellness Center in Cleveland and at the MetroHealth Strongsville Community Health Center.

According to Dr. Auckley, insomnia, sleep apnea, narcolepsy, restless legs syndrome and parasomnias, such as sleep walking and night terrors, are the main types of sleep disorders diagnosed and treated at the Center for Sleep Medicine. Insomnia is the most common, with 25% of Americans experiencing it intermittently and 10% chronically. It is especially common in women and the elderly, and the causes vary — from environmental conditions to poor sleep habits to medical or psychological conditions and sometimes even medications. Read the rest of this entry

A new study found that certain oxygen saturation parameters were improved by one dose of sleep apnea treatment CX1739, but findings also showed a reduced sleep time during the night following drug treatment. Moreover, CX1739 did not reduce the mean apnea/hypopnea index (AHI).

The study enrolled 20 relatively healthy adults with moderate-to-severe obstructive sleep apnea; 16 were administered a single oral dose of CX1739 and four received matching placebo for 1 night. The objective of the study was to further explore safety and tolerability in the sleep apnea population, as well as to assess putative efficacy of CX1739 on a range of sleep apnea parameters assessed by overnight polysomnography.

“A single dose of CX1739 improved a number of sleep apnea parameters across most of the 16 subjects who were given the drug, and there were some CX1739-treated subjects who demonstrated a robust reduction in sleep apnea symptoms,” said Mark Varney, PhD, president and CEO of Cortex, developer of the drug. Read the rest of this entry

SleepApneaDisorder/[ Press Release ]/ Cortex Pharmaceuticals, Inc. announced top-line results from an exploratory clinical study with its AMPAKINE® compound, CX1739 in subjects with sleep apnea. The study enrolled 20 relatively healthy adults with moderate-to-severe obstructive sleep apnea, 16 of which were administered a single oral dose of CX1739 and 4 of which received matching placebo for one night.

The objective of the study was to further explore safety and tolerability in the sleep apnea population, as well as to assess putative efficacy of CX1739 on a range of sleep apnea parameters assessed by overnight polysomnography.

The study demonstrated that selected oxygen saturation parameters were statistically improved by one dose of CX1739, but the interpretation of these results was complicated by a reduced sleep time during the night following drug treatment. 

CX1739 did not reduce the mean apnea/hypopnea index (AHI; frequency of apnea or hypopnea events per hour of sleep). However, in the AHI responder analysis, defined as a greater than 40% reduction in the AHI, three subjects (20%) in the CX1739 treatment group were responders, and there were no responders in the placebo group. Read the rest of this entry

UAE Philips conducted an online Sleep Apnea Awareness campaign titled Do You Snore, to help build public consciousness about Obstructive Sleep Apnea (OSA) in the UAE. Email invitations were sent out to fill out a short and straight forward survey to more than 200,000 recipients based in the country, targeting a sample group of the age 25 and above.

A high number of respondents showed positive results and are very likely to be suffering fromObstructive Sleep Apnea ( OSA). The potential patients were advised to print their report and seek further medical advice and diagnostic tests for sleep apnea.

Obstructive Sleep Apnea is one of the most common sleep disorders worldwide. It is a condition that causes a persons breathing to stop repeatedly during the night, causing disruption in their sleep as they struggle to breathe. As a result, they never get the deep, restorative sleep that is needed. Obstructive sleep apnea (OSA) can not only negatively impact a persons overall quality of life and productivity, but it can also potentially lead to serious health issues like increasing the risk of type 2 diabetes, high blood pressure, abnormal heart rhythm, strokes and other conditions. Read the rest of this entry

In a recently completed research study the researchers examined that among children undergoing adenotonsillectomy for obstructive sleep apnea, what are the responsible factors that promote incomplete resolution of obstructive sleep apnea.

In quest to this exploration researchers  attempted to assess the efficacy of surgical removal of the tonsils and adenoids (adenotonsillectomy [AT]) in the treatment of obstructive sleep apnea (OSA) in children, and to delineate factors associated with persistent OSA, a retrospective review of pre- and postsurgery polysomnograms (PSG) through a research study which was conducted at eight facilities in the US and Europe. Read the rest of this entry

Lake City Community Hospital recently installed the Carolina Sleep Lab, a two-bed sleep lab used to perform tests for sleep disorders.

A health-care specialist can order an overnight sleep study known as a polysomnogram if he or she suspects a patient has a sleep disorder such as sleep apnea, in which breathing repeatedly stops and starts. Read the rest of this entry

Related Posts with Thumbnails
 Page 1 of 1  1